These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 17348847)
1. Current concepts for the combined treatment modality of ionizing radiation with anticancer agents. Oehler C; Dickinson DJ; Broggini-Tenzer A; Hofstetter B; Hollenstein A; Riesterer O; Vuong V; Pruschy M Curr Pharm Des; 2007; 13(5):519-35. PubMed ID: 17348847 [TBL] [Abstract][Full Text] [Related]
2. Signal transduction inhibitors as radiosensitizers. Tenzer A; Zingg D; Riesterer O; Vuong V; Bodis S; Pruschy M Curr Med Chem Anticancer Agents; 2002 Nov; 2(6):727-42. PubMed ID: 12678723 [TBL] [Abstract][Full Text] [Related]
3. Nutlins and ionizing radiation in cancer therapy. Impicciatore G; Sancilio S; Miscia S; Di Pietro R Curr Pharm Des; 2010; 16(12):1427-42. PubMed ID: 20166982 [TBL] [Abstract][Full Text] [Related]
4. Experimental results and clinical implications of the four R's in fractionated radiotherapy. Trott KR Radiat Environ Biophys; 1982; 20(3):159-70. PubMed ID: 7051129 [TBL] [Abstract][Full Text] [Related]
5. Current and emerging strategies to increase the efficacy of ionizing radiation in the treatment of cancer. Berdis AJ Expert Opin Drug Discov; 2014 Feb; 9(2):167-81. PubMed ID: 24372166 [TBL] [Abstract][Full Text] [Related]
6. The influence of ketogenic therapy on the 5 R's of radiobiology. Klement RJ Int J Radiat Biol; 2019 Apr; 95(4):394-407. PubMed ID: 28905672 [TBL] [Abstract][Full Text] [Related]
7. Combining anti-tumor alkyl-phospholipid analogs and radiotherapy: rationale and clinical outlook. Verheij M; Moolenaar WH; Blitterswijk WJ Anticancer Agents Med Chem; 2014 May; 14(4):618-28. PubMed ID: 24628238 [TBL] [Abstract][Full Text] [Related]
8. [Death inducing ligands in combination with ionizing radiation: objective and current knowledge]. Belka C; Betsch A; Marini P; Jendrossek V; Bamberg M; Budach W Strahlenther Onkol; 2003 Mar; 179(3):141-51. PubMed ID: 12627256 [TBL] [Abstract][Full Text] [Related]
9. New radiosensitizing regimens, drugs, prodrugs, and candidates. Vallerga AK; Zarling DA; Kinsella TJ Clin Adv Hematol Oncol; 2004 Dec; 2(12):793-805. PubMed ID: 16166960 [TBL] [Abstract][Full Text] [Related]
10. Strategizing the clone wars: pharmacological control of cellular sensitivity to radiation. Kimple RJ Mol Interv; 2010 Dec; 10(6):341-53. PubMed ID: 21263160 [TBL] [Abstract][Full Text] [Related]
11. Cellular responses to ionizing radiation damage. Li L; Story M; Legerski RJ Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1157-62. PubMed ID: 11240259 [TBL] [Abstract][Full Text] [Related]
12. Ionizing radiation-induced bystander effects, potential targets for modulation of radiotherapy. Rzeszowska-Wolny J; Przybyszewski WM; Widel M Eur J Pharmacol; 2009 Dec; 625(1-3):156-64. PubMed ID: 19835860 [TBL] [Abstract][Full Text] [Related]
14. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Wachsberger P; Burd R; Dicker AP Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357 [TBL] [Abstract][Full Text] [Related]
15. Ionizing radiation-induced risks to the central nervous system and countermeasures in cellular and rodent models. Pariset E; Malkani S; Cekanaviciute E; Costes SV Int J Radiat Biol; 2021; 97(sup1):S132-S150. PubMed ID: 32946305 [TBL] [Abstract][Full Text] [Related]
16. Is tumor (R)ejection by the immune system the "5th R" of radiobiology? Golden EB; Formenti SC Oncoimmunology; 2014 Jan; 3(1):e28133. PubMed ID: 24800177 [TBL] [Abstract][Full Text] [Related]
17. Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation. Ohneseit PA; Wildemann A; Herskind C; Bamberg M; Rodemann HP Int J Radiat Biol; 2002 Feb; 78(2):125-32. PubMed ID: 11779362 [TBL] [Abstract][Full Text] [Related]
18. A role for molecular radiobiology in radiotherapy? Gordon AT; McMillan TJ Clin Oncol (R Coll Radiol); 1997; 9(2):70-8. PubMed ID: 9135890 [TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation. Toulany M; Rodemann HP Semin Cancer Biol; 2015 Dec; 35():180-90. PubMed ID: 26192967 [TBL] [Abstract][Full Text] [Related]
20. [Biomodulation and radiotherapy]. Bourhis J; Lartigau E Cancer Radiother; 2000 Nov; 4 Suppl 1():128s-133s. PubMed ID: 11194950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]